One of the leading public IP licensing companies, or PIPCOs, Tessera Holding Corporation, has changed its name to Xperi Corporation, an indication that it has
Category: Transactions
Pre-IPO Snap, with $25B valuation, paid $9M for 245 IBM patents
A soft market for patent licensing has not stopped the right patent portfolio from commanding a respectable price from the right buyer – at the
‘Innocent’ IP theft is widely accepted and dangerously viral – Why?
So widespread is IP abuse that it no longer is regarded as a crime by many of the people committing it or authorities entrusted to
Experts: Void from U.S. patent “train wreck” is being filled by China’s patent system
In a few short years China’s patent system has gone from an IP rights wannabe to one of the most responsive and patent-friendly systems in
China is poised to overtake the U.S. as the leading patent system
A few years ago a company whose patents were violated in China had little or no chance of defending its rights. Determined to move beyond
InterDigital leads PIPX public IP stock index to a 44.9% gain for 2016
The PIPX public IP licensing company stock index soared to a 44.9% increase in 2016, led by an impressive 86.3% move for InterDigital. With a
IP CloseUp visits were up 81% in 2016, breaking previous record
It was the second record-breaking year in a row for IP CloseUp readership, with 43,946 visits in 2016, an 81% increase from 24,273 in 2015.
Trump Jr.’s op-ed reveals a solid understanding of patent licensing
Donald J. Trump, Jr.’s editorial in the The Daily Caller in 2012, a conservative leaning publication that generates more than 16 million monthly visits, indicates that
Gov’t study of economic impact of patent infringement is needed ASAP, experts say
There are abundant statistics on the cost of counterfeit goods, copyright infringement and even the negative impact of patent “trolls,” but nothing on the estimated
New venture boosts leading medical researchers & their IP rights
A unique public-private partnership provides medical research centers and the patents they generate with a more efficient and rewarding path toward commercialization. Bridge Medicines is a drug discovery
Attorney-investor is willing to share patent filing costs & risks with clients
Many law firms still seek to participate in the outcome of clients’ patent litigation, but few are willing to share the cost of obtaining and
EFF’s narrow position on university tech transfer is “wildly misguided”
The Electronic Frontier Foundation (EFF) is attempting to paint a scarlet letter on universities with public funding who benefit from sharing discoveries with those best-equipped
ipcloseup.com 